Axsome Therapeutics AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
JAZZ Stock | USD 121.59 1.05 0.86% |
Slightly above 73% of Jazz Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Jazz Pharmaceuticals PLC stock suggests that many investors are alarmed at this time. Jazz Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Jazz Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Jazz |
On Tuesday, Axsome Therapeutics Inc said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo in Phase 3 ENCORE trial. AXS-12 was also well tolerated with long-term dosing, and its safety profile was consistent with that observed in previously completed trials. The primary endpoint was achieved with patients randomized to switch to placebo experiencing a mean increase of 10.29 cataplexy attacks per week compar
Read at finance.yahoo.com
Jazz Pharmaceuticals PLC Current Investor Sentiment
Panic Vs Confidence
27
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Jazz Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Jazz Pharmaceuticals PLC.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentDisposing |
Jazz Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Jazz Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Jazz Pharmaceuticals PLC Historical Investor Sentiment
Investor biases related to Jazz Pharmaceuticals' public news can be used to forecast risks associated with an investment in Jazz. The trend in average sentiment can be used to explain how an investor holding Jazz can time the market purely based on public headlines and social activities around Jazz Pharmaceuticals PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Jazz Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Jazz Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Jazz Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Jazz Pharmaceuticals.
Jazz Pharmaceuticals Fundamental Analysis
We analyze Jazz Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Jazz Pharmaceuticals is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Jazz Pharmaceuticals PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jazz Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Jazz Pharmaceuticals Related Equities
EXEL | Exelixis | 1.48 | ||||
BPMC | Blueprint Medicines | 1.35 | ||||
BMRN | Biomarin Pharmaceutical | 0.93 | ||||
PCVX | Vaxcyte | 0.38 | ||||
ARGX | Argenx NV | 0.32 | ||||
TECH | Bio Techne | 0.03 | ||||
ASND | Ascendis Pharma | 0.18 | ||||
ALNY | Alnylam Pharmaceuticals | 0.26 | ||||
HALO | Halozyme Therapeutics | 0.56 | ||||
LQDA | Liquidia Technologies | 0.60 | ||||
APLS | Apellis Pharmaceuticals | 0.62 | ||||
DNLI | Denali Therapeutics | 0.64 | ||||
RARE | Ultragenyx | 1.04 | ||||
INCY | Incyte | 1.14 | ||||
VRDN | Viridian Therapeutics | 1.46 | ||||
UTHR | United Therapeutics | 2.02 | ||||
INBX | Inhibrx | 2.37 | ||||
LEGN | Legend Biotech | 2.46 | ||||
PTGX | Protagonist Therapeutics | 2.56 | ||||
LRMR | Larimar Therapeutics | 4.67 |
Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.